Below are the most recent publications written about "Triterpenes" by people in Profiles.
-
Sarkar S, Zadrozny KK, Zadorozhnyi R, Russell RW, Quinn CM, Kleinpeter A, Ablan S, Meshkin H, Perilla JR, Freed EO, Ganser-Pornillos BK, Pornillos O, Gronenborn AM, Polenova T. Structural basis of HIV-1 maturation inhibitor binding and activity. Nat Commun. 2023 03 04; 14(1):1237.
-
Goje O, Sobel R, Nyirjesy P, Goldstein SR, Spitzer M, Faught B, Larson S, King T, Azie NE, Angulo D, Sobel JD. Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306. J Womens Health (Larchmt). 2023 02; 32(2):178-186.
-
Nyirjesy P, Schwebke JR, Angulo DA, Harriott IA, Azie NE, Sobel JD. Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. Clin Infect Dis. 2022 07 06; 74(12):2129-2135.
-
Schwebke JR, Sobel R, Gersten JK, Sussman SA, Lederman SN, Jacobs MA, Chappell BT, Weinstein DL, Moffett AH, Azie NE, Angulo DA, Harriott IA, Borroto-Esoda K, Ghannoum MA, Nyirjesy P, Sobel JD. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clin Infect Dis. 2022 06 10; 74(11):1979-1985.
-
Cohen-Nowak AJ, Cohen AJ, Correia ED, Portocarrero CP, South AP, Nikbakht N. Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model. Exp Dermatol. 2022 07; 31(7):1083-1088.
-
Sobel R, Nyirjesy P, Ghannoum MA, Delchev DA, Azie NE, Angulo D, Harriott IA, Borroto-Esoda K, Sobel JD. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a?global phase 3, randomised, placebo-controlled superiority study (VANISH 306). BJOG. 2022 02; 129(3):412-420.
-
Luginbuhl AJ, Hobelmann K, Rodin J, Shukla S, Rodeck U, Linnenbach A. Synthetic Triterpenoid RTA-408: Limits Radiation Damage to Normal Tissue. Laryngoscope. 2022 06; 132(6):1196-1204.
-
Petraitis V, Petraitiene R, Katragkou A, Maung BBW, Naing E, Kavaliauskas P, Barat S, Borroto-Esoda K, Azie N, Angulo D, Walsh TJ. Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1?3)-?-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2020 05 21; 64(6).
-
Zhang Y, Li X, Ciric B, Curtis MT, Chen WJ, Rostami A, Zhang GX. A dual effect of ursolic acid to the treatment of multiple sclerosis through both immunomodulation and direct remyelination. Proc Natl Acad Sci U S A. 2020 04 21; 117(16):9082-9093.
-
Goldman DC, Alexeev V, Lash E, Guha C, Rodeck U, Fleming WH. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice. Radiat Res. 2015 Mar; 183(3):338-44.